乐
乐观
乐观 · 25%HKPD
$1.53
情景价格
$1.450
+0.096 (+6.62%)收盘时
Loading chart…
- 最高
- 1.600
- 开盘
- 1.420
- 成交量加权均价
- 1.47
- 成交量
- 48.81K
- 市值
- —
- 最低
- 1.360
- 成交额
- 71.76K
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
AI 分析 of Cellyan Biotechnology Co Ltd (HKPD)
卖出Given the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
估值指标
Cellyan Biotechnology Co Ltd（HKPD）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。
Alphio AI 对 HKPD 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
7.007-17NASDAQ.COMCellyan Biotechnology Receives Nasdaq Compliance Extension
8.507-16seekingalphaCellyan Biotechnology Secures Nasdaq Compliance Extension
- 8.501-16seekingalpha
Cellyan Biotechnology (HKPD) Receives Nasdaq Warning for Non-Compliance with $1 Minimum Bid Price
7.001-16GlobenewswireCellyan Biotechnology Receives Nasdaq Notification for Share Price Below $1
- 9.012-17Globenewswire
HKPD Approves Major Capital Restructuring at 2025 Annual Meeting
HKPD 常见问题 —— 由 Alphio AI 解答
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.
Given the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。